See more : Elysee Development Corp. (ASXSF) Income Statement Analysis – Financial Results
Complete financial analysis of Outlook Therapeutics, Inc. (OTLK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Outlook Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- HELMA Eigenheimbau Aktiengesellschaft (0W0T.L) Income Statement Analysis – Financial Results
- Odontoprev S.A. (ODPV3.SA) Income Statement Analysis – Financial Results
- freenet AG (FRTAY) Income Statement Analysis – Financial Results
- Kimberly-Clark Corporation (KMY.DE) Income Statement Analysis – Financial Results
- Henkel AG & Co. KGaA (HEN.DE) Income Statement Analysis – Financial Results
Outlook Therapeutics, Inc. (OTLK)
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.15M | 3.09M | 3.81M | 2.98M | 5.22M | 9.05M |
| Cost of Revenue | 0.00 | 44.19K | 204.69K | 262.14K | 554.07K | 23.81K | 18.50K | 23.81K | 32.76K | 38.88K | 14.12K |
| Gross Profit | 0.00 | -44.19K | -204.69K | -262.14K | -554.07K | 8.12M | 3.07M | 3.79M | 2.95M | 5.18M | 9.04M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 99.71% | 99.40% | 99.38% | 98.90% | 99.26% | 99.84% |
| Research & Development | 41,763.05B | 26.45M | 42.33M | 38.96M | 26.34M | 23.81M | 18.50M | 23.81M | 32.76M | 38.88M | 14.12M |
| General & Administrative | 29,940.19B | 26.67M | 20.74M | 12.77M | 9.97M | 9.37M | 14.23M | 15.88M | 21.64M | 12.91M | 7.32M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 279.68K | -1.90M | -3.85M | -7.25M | -2.69M | -2.47M | 0.00 | 0.00 |
| SG&A | 29,940.19B | 26.67M | 20.74M | 13.05M | 8.08M | 5.52M | 6.97M | 13.19M | 19.17M | 12.91M | 7.32M |
| Other Expenses | 0.00 | 0.00 | -882.90K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 71,703.24B | 53.13M | 63.07M | 51.73M | 36.31M | 29.33M | 25.48M | 39.69M | 51.93M | 51.78M | 21.44M |
| Cost & Expenses | 0.00 | 53.13M | 63.07M | 51.73M | 36.31M | 32.69M | 28.53M | 39.69M | 54.74M | 51.78M | 21.44M |
| Interest Income | -906.15B | 1.56K | 1.49K | 936.13 | 1.76K | 3.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3,156.96B | 1.56M | 1.49M | 936.00K | 1.76M | 3.47M | 3.89M | 5.63M | 1.47M | 2.30M | 901.05K |
| Depreciation & Amortization | 0.00 | 44.19K | 204.69K | 262.14K | 554.07K | 3.36M | 3.05M | 2.69M | 2.39M | 1.82M | 878.48K |
| EBITDA | -71,703.24B | -57.38M | -62.87M | -51.46M | -35.76M | -31.11M | -26.79M | -30.03M | -48.95M | -44.74M | -11.51M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -265.98% | -725.17% | -870.73% | -1,656.75% | -857.18% | -127.22% |
| Operating Income | -71,703.24B | -53.13M | -63.07M | -51.73M | -36.84M | -36.30M | -25.44M | -35.88M | -51.76M | -46.56M | -12.39M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -445.60% | -824.09% | -941.36% | -1,737.10% | -892.13% | -136.92% |
| Total Other Income/Expenses | -3,660.68B | -5.85M | -2.98M | -1.43M | -1.67M | -1.64M | -4.10M | -2.47M | -1.85M | -2.30M | -901.05K |
| Income Before Tax | -75,363.91B | -58.98M | -66.05M | -53.16M | -38.51M | -37.93M | -33.74M | -38.35M | -53.23M | -48.86M | -13.29M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -465.68% | -1,092.78% | -1,006.10% | -1,786.37% | -936.15% | -146.88% |
| Income Tax Expense | 2.80B | 2.80K | 2.80K | 2.00K | -3.27M | -3.41M | -3.65M | 501.50K | 103.00K | -190.11K | 439.02K |
| Net Income | -75,366.71B | -58.98M | -66.05M | -53.16M | -35.24M | -34.52M | -46.11M | -38.85M | -53.33M | -47.39M | -13.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -423.81% | -1,493.57% | -1,019.26% | -1,789.83% | -908.05% | -151.73% |
| EPS | -4.06K | -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.70 | -258.75 | -495.71 | -504.47 | -155.35 |
| EPS Diluted | -4.06K | -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.70 | -258.54 | -495.71 | -504.47 | -155.35 |
| Weighted Avg Shares Out | 18.55B | 12.51M | 10.60M | 7.63M | 3.63M | 909.59K | 909.59K | 150.14K | 107.58K | 93.95K | 88.40K |
| Weighted Avg Shares Out (Dil) | 18.55B | 12.51M | 10.60M | 7.63M | 3.63M | 909.59K | 909.59K | 150.26K | 107.58K | 93.95K | 88.40K |
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
ISELIN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation...
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
ISELIN, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation...
Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles
Outlook Therapeutics faces liquidity issues and delays in FDA approval for its Wet AMD therapy, leading to a downgrade from Strong Buy to Buy. The potential blockbuster market for LYTENAVA in treating Wet AMD is significant, but FDA hurdles and...
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update
ISELIN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment...
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that Russell Trenary, President and CEO...
Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast
ISELIN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment...
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
Company to participate in a fireside chat on Monday, August 5 th at 8:00 AM ET
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for...
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
ISELIN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that the United Kingdom (UK) Medicines...
Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
It's essential to remember that low-float biopharmaceutical companies often experience volatility due to frequent breaking news and technical factors such as float size and short interest. While the bullish price target is noteworthy, it's crucial to delve deeper into the...
Source: https://incomestatements.info
Category: Stock Reports